Smith & Nephew plc vs Snowflake Inc — how do they compare? Smith & Nephew plc trades at $27.08 (market cap $11.10B), while Snowflake Inc trades at $359.77 (market cap $121.15B). The key difference: Snowflake Inc is far larger — about 10.9× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and Snowflake Inc for 54 Days on average.
| SNN | SNOW | |
|---|---|---|
Market Cap | $11.10B | $121.15B |
Volume | 1,051,703 | 3,986,549 |
Sector | Health | Technology |
52-Week High | $37.17 | $356.47 |
52-Week Low | $26.42 | $121.11 |
Typical Hold Time | 120 Days | 54 Days |
Enterprise Value | $14.13B | $121.57B |
Dividend Yield | 2.95% | — |
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Snowflake (SNOW) trades at $360.12, up 8.19% in the past 24 hours, with strong technical momentum and bullish moving average signals. The company continues to show impressive revenue growth, reaching $3.63 billion in 2025, though it remains unprofitable with a net loss of $1.29 billion. Recent developments include a $3.75 billion convertible note offering and expanded partnerships with UiPath, while analysts maintain strong buy sentiment with an $418.03 consensus price target.
Snowflake presents a growth investment opportunity with accelerating revenue expansion and positive earnings beats, but faces significant execution risk due to persistent losses and high valuation multiples. The stock's 81% analyst buy rating reflects confidence in the company's AI data cloud positioning, though investors must weigh the premium valuation against ongoing profitability challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →